External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ADPD 2023
Roche and Genentech at

ADPD 2023

March 28 - April 01
Gothenburg, Sweden / hybrid (virtual)
adpd.kenes.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:00 AM
Duration 15mins Gothenburg, Sweden / hybrid (virtual)
A Phase 1b Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Selnoflast, a Novel NLRP3 Inflammasome Inhibitor, in Early Stage Parkinson’s Disease: Rationale and Study Design
Gennaro Pagano, Giulia D’Urso, Alessandra E. Thomann, Judith Anzures Cabrera, Bastian Zinnhardt, Benedicte Ricci, Lorna Bailey, Krzysztof Smigorski, Venissa Machado, Eva Zsuzsanna Mracsko, Nicola Pavese, Kenneth Marek, Kathrin Brockmann, Tanya Simuni, Nicoletta, Milani Muelhardt
Neuroscience | Parkinson's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 15mins On demand
The AD Workbench NeuroToolkit Application (NTKapp) suite: cloud-based tools for secure collaborative research in Alzheimer’s Disease
Logan C, Bauer A, Bentink S, Rosenfeld E, Maxim A, Tomsa R, McHugh C, Clement M, Suridjan I, Carboni M
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 15mins On demand Gallery E
THE ABOUT ME CARE CARD: AN SHARED DECISION-MAKING (SDM)-BASED TOOL TO PROMOTE PURPOSEFUL DEMENTIA CARE
Mr Greg Kotzbauer, Dr Mikele Epperly, Ms Yee Huey Tan, Ms Supriya Yagnik, Dr Heather Kang, and Prof. Stuart Grande
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:20 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: EFFICACY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Bateman R, Smith J, Donohue M, Delmar P, Gruendl E, Boada M, Rutten-Jacobs L, Lane C, Cummings J, Fontoura P, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: SAFETY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Salloway S, Lyons M, Lane C, Rossomanno S, Wojtowicz J, Plank R, Warren F, Smith J, Boada M, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:50 PM
Duration 15mins Hall F4+F5
Effect of Age, Body Mass Index and Apolipoprotein E Genotype on Plasma Biomarkers of Amyloid Pathology
Carboni M, Hortsch S, Kurka H, Khoroshevsk A, Kollmorgen G, Jethwa A, Blennow K, Masters CL
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:50 PM
Duration 15mins HALL F1+F2+F3
ALUMNI AD STUDY DESIGN:Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease
Seleri Assuncao S, Brangman S, Henderson J, Parker M, Monroe S, Mintzer J, Wise-Brown A, Grundman M, Smith J, Doody R, Lin H, Assman B, Rippon G
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:05 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II RESULTS: EFFECT OF SUBCUTANEOUS GANTENERUMAB ON FLUID BIOMARKERS OF AD PATHOLOGY AND NEURODEGENERATION
Bittner T, Blennow K, Scelsi M, Palermo G, Kollmorgen G, Smith J, Zetterberg H, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:20 PM
Duration 15mins HALL F1+F2+F3
GRADUATE I AND II: IMAGING FINDINGS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB IN EARLY ALZHEIMER’S DISEASE
Barkhof F, Klein G, Tonietto M, Bittner T, Ahlers S, Abbas R, MD, Smith J, Fox N, Black S, Hansson O, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:10 PM
Duration 15mins ONSITE - HALL G4
ATTITUDES OF NEUROLOGISTS TOWARDS THE USE OF BIOMARKERS IN THE DIAGNOSIS OF EARLY-STAGE ALZHEIMER'S DISEASE
Elena Garcia Arcelay, Luisa Guglielmini, Marie Bordone, Alonso Montoya, Jorge Maurino, Guillermo Garcia-Ribas
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.